Milestone Pharmaceuticals enrolls first European patient in Phase 3 AFib‑RVR trial
Milestone Pharmaceuticals announced that the first European participant was enrolled at a Dutch Cardiovascular Investigator Network site in the Netherlands for its ReVeRA‑301 Phase 3 study of etripamil nasal spray. The trial targets roughly 150 patient events with AFib‑RVR and uses the same 70 mg repeat‑dose regimen approved in the United States for PSVT. Enrollment in the United States began in August 2026 and has since expanded to Canada.
Why it matters
Milestone says the European enrollment shows continued global progress and helps de‑risk the pivotal study, potentially accelerating its supplemental NDA filing. Successful completion of the trial could broaden the approved use of CARDAMYST and drive revenue growth.
Key facts
- 1The first European patient was enrolled at a site within the Dutch Cardiovascular Investigator Network in the Netherlands. globenewswire.com
- 2ReVeRA‑301 aims to enroll approximately 150 AFib‑RVR patient events. globenewswire.com
- 3The trial evaluates the same 70 mg repeat‑dose regimen of etripamil nasal spray that is FDA‑approved for PSVT. globenewswire.com
- 4U.S. enrollment for ReVeRA‑301 started in August 2026 and has expanded to Canada. globenewswire.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.